ProPhase Labs (NASDAQ:PRPH) Announces Earnings Results, Beats Expectations By $0.21 EPS

ProPhase Labs (NASDAQ:PRPHGet Free Report) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.21, Zacks reports. ProPhase Labs had a negative net margin of 82.18% and a negative return on equity of 42.89%. The firm had revenue of $3.63 million for the quarter, compared to analyst estimates of $9.86 million. During the same quarter last year, the business earned $0.03 earnings per share.

ProPhase Labs Trading Up 2.6 %

Shares of PRPH traded up $0.13 during mid-day trading on Friday, reaching $5.05. The company had a trading volume of 32,777 shares, compared to its average volume of 108,359. The stock has a market cap of $91.15 million, a price-to-earnings ratio of -4.68 and a beta of -0.17. The firm has a fifty day simple moving average of $5.57 and a 200-day simple moving average of $5.05. ProPhase Labs has a fifty-two week low of $4.05 and a fifty-two week high of $9.94. The company has a current ratio of 2.28, a quick ratio of 2.10 and a debt-to-equity ratio of 0.29.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a research report on Wednesday, February 21st.

Check Out Our Latest Stock Analysis on PRPH

About ProPhase Labs

(Get Free Report)

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Read More

Earnings History for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.